Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...
Recursion OS applies machine learning and high-content screening methods in what the companies said would be a “transformational” model for tech-enabled target and drug discovery. The integrated, ...
The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...
Recursion Pharmaceuticals uses high-dimensional data and modern approaches to generate predictive results for drug discovery and development. The company has strengthened its tech stack through ...
At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...
There is also a chance it could be facing some serious challenges. Collaborations with bigger companies could be a help along the way. Today, Recursion has no products approved for sale. By early 2029 ...
PHILADELPHIA - Recursion (NASDAQ: RXRX), a clinical stage TechBio company with a market capitalization of $2.27 billion, has entered into a licensing agreement with HealthVerity to utilize its ...
Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify 100 ...
We are in the midst of an unstructured data revolution – with 80% of data likely to be unstructured by 2025, according to IDC. The rise of advanced analytics and in particular artificial ...
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback